Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 4/20 | 0.63 |
| ▸ | SRC | P12931 | 4/20 | 0.60 |
| ▸ | IKBKB | O14920 | 10/20 | 0.53 |
| ▸ | CHUK | O15111 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116493 | 0.83 | CA12 (0.52) | ABL1CA12CA2SRCIKBKB | |
| SCHEMBL5106125 | 0.75 | KDM1A (0.62) | — | |
| SCHEMBL4265736 | 0.75 | SRC (1.00) | ABL1SRC | |
| SCHEMBL6973412 | 0.74 | ALDH1A1 (0.60) | — | |
| SCHEMBL4275797 | 0.73 | SRC (1.00) | ABL1SRC | |
| Hydrochloric Acid SCHEMBL4274340 | 0.72 | SRC (0.98) | ABL1SRC | |
| SCHEMBL5120446 | 0.72 | CA12 (0.46) | ABL1CA12CA2SRCIKBKB | |
| SCHEMBL28897265 | 0.71 | ALDH1A1 (0.64) | — | |
| SCHEMBL27717443 | 0.71 | IKBKB (0.58) | ABL1CA12CA2SRCIKBKB | |
| SCHEMBL5436724 | 0.70 | IKBKB (0.57) | ABL1CA12CA2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | claimed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | ABL1 140/4885CA12 1880/4885CA2 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.